| Dr Richard M Orlan, MD | |
|
19 Belmont Ave, Suite 1201, Brattleboro, VT 05301-7109 | |
| (802) 275-3640 | |
| (802) 275-3675 |
| Full Name | Dr Richard M Orlan |
|---|---|
| Gender | Male |
| Speciality | Geriatric Medicine |
| Experience | 43 Years |
| Location | 19 Belmont Ave, Brattleboro, Vermont |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700854379 | NPI | - | NPPES |
| 1015520 | Medicaid | VT | |
| 377156300 | Medicaid | FL |
| Facility Name | Location | Facility Type |
|---|---|---|
| Rutland Regional Medical Center | Rutland, VT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Community Health Centers Of The Rutland Region Inc | 2961467386 | 85 |
| Isaac Health Florida Professional Association | 1850767880 | 7 |
News Archive
Flamel Technologies today announced the initiation of a Phase 2a clinical trial of Flamel's Interferon alpha-2b XL (IFN-alpha-2b XL), which is based on Flamel's Medusa® platform for controlled release of biologics. IFN-alpha-2b XL is being developed as a controlled release of unmodified interferon alpha-2b for the treatment of chronic hepatitis C virus (HCV).
Shortly after a mouse embryo starts to form, some of its stem cells undergo a dramatic metabolic shift to enter the next stage of development, Seattle researchers report today. These stem cells start using and producing energy like cancer cells.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD).
New strides are being made toward the ex vivo growth of human lungs. In a new article published in Tissue Engineering, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers, researchers report the development of a high-throughput, automated, multichannel lung bioreactor that allows parallel culture of up to five human cell-populated isolated rat lung scaffolds.
› Verified 9 days ago
| Entity Name | Community Health Centers Of The Rutland Region Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336193838 PECOS PAC ID: 2961467386 Enrollment ID: O20041129000357 |
News Archive
Flamel Technologies today announced the initiation of a Phase 2a clinical trial of Flamel's Interferon alpha-2b XL (IFN-alpha-2b XL), which is based on Flamel's Medusa® platform for controlled release of biologics. IFN-alpha-2b XL is being developed as a controlled release of unmodified interferon alpha-2b for the treatment of chronic hepatitis C virus (HCV).
Shortly after a mouse embryo starts to form, some of its stem cells undergo a dramatic metabolic shift to enter the next stage of development, Seattle researchers report today. These stem cells start using and producing energy like cancer cells.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD).
New strides are being made toward the ex vivo growth of human lungs. In a new article published in Tissue Engineering, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers, researchers report the development of a high-throughput, automated, multichannel lung bioreactor that allows parallel culture of up to five human cell-populated isolated rat lung scaffolds.
› Verified 9 days ago
| Entity Name | Community Health Centers Of The Rutland Region Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073567590 PECOS PAC ID: 2961467386 Enrollment ID: O20041129000784 |
News Archive
Flamel Technologies today announced the initiation of a Phase 2a clinical trial of Flamel's Interferon alpha-2b XL (IFN-alpha-2b XL), which is based on Flamel's Medusa® platform for controlled release of biologics. IFN-alpha-2b XL is being developed as a controlled release of unmodified interferon alpha-2b for the treatment of chronic hepatitis C virus (HCV).
Shortly after a mouse embryo starts to form, some of its stem cells undergo a dramatic metabolic shift to enter the next stage of development, Seattle researchers report today. These stem cells start using and producing energy like cancer cells.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD).
New strides are being made toward the ex vivo growth of human lungs. In a new article published in Tissue Engineering, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers, researchers report the development of a high-throughput, automated, multichannel lung bioreactor that allows parallel culture of up to five human cell-populated isolated rat lung scaffolds.
› Verified 9 days ago
| Entity Name | Community Health Centers Of The Rutland Region Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104870922 PECOS PAC ID: 2961467386 Enrollment ID: O20050131001023 |
News Archive
Flamel Technologies today announced the initiation of a Phase 2a clinical trial of Flamel's Interferon alpha-2b XL (IFN-alpha-2b XL), which is based on Flamel's Medusa® platform for controlled release of biologics. IFN-alpha-2b XL is being developed as a controlled release of unmodified interferon alpha-2b for the treatment of chronic hepatitis C virus (HCV).
Shortly after a mouse embryo starts to form, some of its stem cells undergo a dramatic metabolic shift to enter the next stage of development, Seattle researchers report today. These stem cells start using and producing energy like cancer cells.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD).
New strides are being made toward the ex vivo growth of human lungs. In a new article published in Tissue Engineering, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers, researchers report the development of a high-throughput, automated, multichannel lung bioreactor that allows parallel culture of up to five human cell-populated isolated rat lung scaffolds.
› Verified 9 days ago
| Entity Name | Community Health Centers Of The Rutland Region Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467681114 PECOS PAC ID: 2961467386 Enrollment ID: O20100804000784 |
News Archive
Flamel Technologies today announced the initiation of a Phase 2a clinical trial of Flamel's Interferon alpha-2b XL (IFN-alpha-2b XL), which is based on Flamel's Medusa® platform for controlled release of biologics. IFN-alpha-2b XL is being developed as a controlled release of unmodified interferon alpha-2b for the treatment of chronic hepatitis C virus (HCV).
Shortly after a mouse embryo starts to form, some of its stem cells undergo a dramatic metabolic shift to enter the next stage of development, Seattle researchers report today. These stem cells start using and producing energy like cancer cells.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD).
New strides are being made toward the ex vivo growth of human lungs. In a new article published in Tissue Engineering, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers, researchers report the development of a high-throughput, automated, multichannel lung bioreactor that allows parallel culture of up to five human cell-populated isolated rat lung scaffolds.
› Verified 9 days ago
| Entity Name | Community Health Centers Of The Rutland Region Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780969345 PECOS PAC ID: 2961467386 Enrollment ID: O20120321000420 |
News Archive
Flamel Technologies today announced the initiation of a Phase 2a clinical trial of Flamel's Interferon alpha-2b XL (IFN-alpha-2b XL), which is based on Flamel's Medusa® platform for controlled release of biologics. IFN-alpha-2b XL is being developed as a controlled release of unmodified interferon alpha-2b for the treatment of chronic hepatitis C virus (HCV).
Shortly after a mouse embryo starts to form, some of its stem cells undergo a dramatic metabolic shift to enter the next stage of development, Seattle researchers report today. These stem cells start using and producing energy like cancer cells.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD).
New strides are being made toward the ex vivo growth of human lungs. In a new article published in Tissue Engineering, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers, researchers report the development of a high-throughput, automated, multichannel lung bioreactor that allows parallel culture of up to five human cell-populated isolated rat lung scaffolds.
› Verified 9 days ago
| Entity Name | Gps Physician Group, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881109452 PECOS PAC ID: 9739447400 Enrollment ID: O20180503001779 |
News Archive
Flamel Technologies today announced the initiation of a Phase 2a clinical trial of Flamel's Interferon alpha-2b XL (IFN-alpha-2b XL), which is based on Flamel's Medusa® platform for controlled release of biologics. IFN-alpha-2b XL is being developed as a controlled release of unmodified interferon alpha-2b for the treatment of chronic hepatitis C virus (HCV).
Shortly after a mouse embryo starts to form, some of its stem cells undergo a dramatic metabolic shift to enter the next stage of development, Seattle researchers report today. These stem cells start using and producing energy like cancer cells.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD).
New strides are being made toward the ex vivo growth of human lungs. In a new article published in Tissue Engineering, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers, researchers report the development of a high-throughput, automated, multichannel lung bioreactor that allows parallel culture of up to five human cell-populated isolated rat lung scaffolds.
› Verified 9 days ago
| Entity Name | Openloop Healthcare Partners Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245820661 PECOS PAC ID: 2668871898 Enrollment ID: O20210923003392 |
News Archive
Flamel Technologies today announced the initiation of a Phase 2a clinical trial of Flamel's Interferon alpha-2b XL (IFN-alpha-2b XL), which is based on Flamel's Medusa® platform for controlled release of biologics. IFN-alpha-2b XL is being developed as a controlled release of unmodified interferon alpha-2b for the treatment of chronic hepatitis C virus (HCV).
Shortly after a mouse embryo starts to form, some of its stem cells undergo a dramatic metabolic shift to enter the next stage of development, Seattle researchers report today. These stem cells start using and producing energy like cancer cells.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD).
New strides are being made toward the ex vivo growth of human lungs. In a new article published in Tissue Engineering, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers, researchers report the development of a high-throughput, automated, multichannel lung bioreactor that allows parallel culture of up to five human cell-populated isolated rat lung scaffolds.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Richard M Orlan, MD Po Box 165, Westminster, VT 05158-0165 Ph: (802) 258-8677 | Dr Richard M Orlan, MD 19 Belmont Ave, Suite 1201, Brattleboro, VT 05301-7109 Ph: (802) 275-3640 |
News Archive
Flamel Technologies today announced the initiation of a Phase 2a clinical trial of Flamel's Interferon alpha-2b XL (IFN-alpha-2b XL), which is based on Flamel's Medusa® platform for controlled release of biologics. IFN-alpha-2b XL is being developed as a controlled release of unmodified interferon alpha-2b for the treatment of chronic hepatitis C virus (HCV).
Shortly after a mouse embryo starts to form, some of its stem cells undergo a dramatic metabolic shift to enter the next stage of development, Seattle researchers report today. These stem cells start using and producing energy like cancer cells.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD).
New strides are being made toward the ex vivo growth of human lungs. In a new article published in Tissue Engineering, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers, researchers report the development of a high-throughput, automated, multichannel lung bioreactor that allows parallel culture of up to five human cell-populated isolated rat lung scaffolds.
› Verified 9 days ago
Eric R Pofcher, M.D. Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 21 Belmont Ave, Brattleboro, VT 05301 Phone: 802-258-3905 Fax: 802-258-4903 | |
Dr. Aida Avdic, MD Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 17 Belmont Ave Ste 1, Brattleboro, VT 05301 Phone: 802-257-0341 Fax: 802-257-8834 | |
Laura S Metsch, MD Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 21 Belmont Ave, Brattleboro, VT 05301 Phone: 802-258-3905 Fax: 802-258-4903 | |
Carolyn Louise Taylor-olson, MD Geriatric Medicine Medicare: Medicare Enrolled Practice Location: 17 Belmont Ave, Brattleboro, VT 05301 Phone: 802-442-8164 | |
Antoine E Soueid, M.D. Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 17 Belmont Ave Ste 1, Brattleboro, VT 05301 Phone: 802-257-0341 Fax: 802-257-8834 | |
Dr. Burton David Tepfer, M.D. Geriatric Medicine Medicare: Medicare Enrolled Practice Location: 19 Belmont Ave, Suite 202, Brattleboro, VT 05301 Phone: 802-257-0505 Fax: 802-257-4665 | |
Dr. Jeffry Brian Potash, MD Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 63 Belmont Ave, Suite 2, Brattleboro, VT 05301 Phone: 802-254-4947 Fax: 802-257-1454 |